WDB coco Co

WDB coco Co Non-Current Assets

The Non-Current Assets of WDB coco Co (7079.T) as of Oct 27, 2026 is -3.69 B JPY. In the previous year, Non-Current Assets was -4.68 B JPY — a change of -21.19% (higher).

Non-Current Assets

-3.69 BJPY

YoY

-21.19%

Last updated:

Non-Current Assets of WDB coco Co is 2026 -3.69 B JPY. Non-Current Assets of WDB coco Co was 2025 -4.68 B JPY. It decreases by -21.19% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WDB coco Co Stock analysis

What does WDB coco Co do? WDB coco Co., Ltd. generates revenue through safety information management services, document support services, development support services, and clinical development support services. The company acts as an agent and support provider for drug development, offering input, evaluation, drafting, and reporting for safety information. Document support services cover QC, translation, and creation of CTD applications for PMDA approval. Development support includes survey form management, document filing, and call center operations. Clinical development support handles clinical trial-related tasks. The primary customers are pharmaceutical companies requiring regulatory compliance and efficient drug development processes. The company serves pharmaceutical firms needing assistance with safety data management, regulatory document preparation, and clinical trial support. Its services are tailored to meet PMDA requirements for marketing approval, particularly through CTD applications. The document support service specifically targets the creation and translation of materials for PMDA submissions. Development support services are utilized by clients managing clinical surveys and trial documentation. Clinical development support is contracted by pharmaceutical companies conducting clinical trials. WDB coco Co., Ltd. provides end-to-end support for drug development lifecycle, from safety data handling to clinical trial management. Its safety information management service is integral for regulatory submissions, while document support ensures compliance with PMDA standards. Development and clinical support services streamline trial operations, reducing time-to-market for pharmaceutical products. The company’s revenue streams are directly tied to the demand for regulatory and clinical support in the pharmaceutical industry. WDB coco Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WDB coco Co stock

Non-Current Assets of WDB coco Co is -3.69 B JPY in 2026.

Non-Current Assets of WDB coco Co changed from -4.68 B JPY to -3.69 B JPY, representing a -21.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets WDB coco Co since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's WDB coco Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — WDB coco Co

All Key Metrics — WDB coco Co